Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kingsbury, S. J.
* Articles by Simpson, G. M.
* Search for Related Content
PubMed
* Articles by Kingsbury, S. J.
* Articles by Simpson, G. M.
Related Collections
* Child/Adolescent Psychiatry
* Cross-Cultural Psychiatry
* Minority Issues
* Treatment Compliance
* Other Forensic Issues
* Skills Training
* Atypical Neuroleptics
* Research Design, Methodology
* Sexual Disorders
* Other Somatic Therapy
Psychiatr Serv 53:214, February 2002
© 2002 American Psychiatric Association


Letters

Rational and Irrational Polypharmacy

Steven J. Kingsbury, M.D., Ph.D., Donna Yi, M.D. and George M. Simpson, M.D.

In Reply: We thank Dr. Fleishman for his comments about our recent article on rational and irrational polypharmacy and appreciate the opportunity to further clarify points we attempted to address in that article. As Dr. Fleishman noted, many patients fail to show an adequate response to a single antipsychotic, even when they receive the optimal dosage, which can set the occasion for using two antipsychotics together. However, in our experience, many patients who are taking two antipsychotics have never been given a trial of clozapine, which appears to have superior efficacy to that of all other antipsychotics.

Further, there is no controlled research on such combinations, only case reports. Therefore, as we stated in our article, we view such combination trials as necessary but experimental. Objective criteria should be used to monitor whether the patient improves, and one of the medications should be discontinued if the patient shows no improvement after an adequate trial—from six to eight weeks. We have also observed many patients on combinations of antipsychotic medications who showed no evidence of improvement according to the chart, the physician, the patient, or the family. We continue to regard this as irrational polypharmacy.





This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kingsbury, S. J.
* Articles by Simpson, G. M.
* Search for Related Content
PubMed
* Articles by Kingsbury, S. J.
* Articles by Simpson, G. M.
Related Collections
* Child/Adolescent Psychiatry
* Cross-Cultural Psychiatry
* Minority Issues
* Treatment Compliance
* Other Forensic Issues
* Skills Training
* Atypical Neuroleptics
* Research Design, Methodology
* Sexual Disorders
* Other Somatic Therapy


Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org